– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a ...

Rallybio is also eligible to receive low single-digit royalties on all future net sales by Recursion. In addition, Rallybio may be eligible to receive certain payments in the event of Recursion ...

Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for the treatment of patients with ...

The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...

Recursion Pharmaceuticals ( (RXRX)) just unveiled an announcement. On July 8, 2025, Recursion Pharmaceuticals acquired full ownership of the ENPP1 inhibitor program, REV102, from Rallybio, aiming ...

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals – Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – ...